On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near. “It’s almost here! The t:slim X2 insulin pump integration with the FreeStyle Libre 3 Plus sensor, the world’s smallest continuous glucose monitor, is coming soon,” Tandem wrote on LinkedIn. Tandem announced that it was […]
abbott
Medtronic gets FDA nods for MiniMed 780G with Abbott Instinct sensor, expansion to type 2
Medtronic (NYSE:MDT) announced today that the FDA granted two major approvals to broaden access to its MiniMed 780G system. First, the FDA granted clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC). This enables integration with a sensor made by Abbott, designed specifically through a collaboration between the medtech giants. Second, the […]
Abbott wins CE mark for Esprit drug-eluting, dissolving scaffold
Abbott (NYSE: ABT) announced today that it received CE mark for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit BTK offers treatment for people with peripheral artery disease (PAD) below the knee (BTK). Abbott designed it to keep arteries open and deliver the drug everolimus to support vessel healing. Following the therapy, the stent completely […]
Medtronic Diabetes shares preview of new Abbott sensor made for MiniMed insulin delivery systems
The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems […]
The 10 largest diabetes technology companies in the world
What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Tidepool launches cloud integration with Abbott CGM
Tidepool announced that it began rolling out its new cloud-to-cloud integration with the Abbott (NYSE:ABT) FreeStyle Libre CGM portfolio. In October 2024, the companies announced a collaboration to deliver cloud-to-cloud integration for an automatic stream of data for patients using Abbott continuous glucose monitors (CGMs) in the U.S. “Every day at Tidepool, we work to […]
Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
Abbott (NYSE:ABT) today reported Street-beating second-quarter results that included significant growth in its Diabetes business. The company’s Medical Device business saw 13.4% growth in reported sales for the quarter. (Read all about the quarterly performance at MassDevice.) Diabetes Care, Heart Failure, Structural Heart and Electrophysiology drove that growth, Abbott said. That included contributions from products like […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Abbott Diabetes head talks Medtronic partnership, exciting times ahead
For many, a partnership between Abbott (NYSE:ABT) and Medtronic (NYSE:MDT), two medtech giants and frequent competitors, would have seemed unlikely. The two companies battle for market share in a variety of spaces, including cardiac implants, vascular access, neuromodulation and more. They’ll continue to duke it out in those areas, but in diabetes, they’ve become collaborators. […]
Abbott could pave new roads in diabetes management with dual sensor on the horizon
About three years ago, Abbott (NYSE:ABT) announced that it had a new diabetes-related biowearable under development. The technology — a dual sensor that continuously monitors glucose and ketone levels — already had FDA breakthrough device designation. Abbott said at the time that it was set for pivotal trial use in 2023, with regulatory submissions to […]
